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Summary.-During the period 1962-71 a total of 2544 patients with respiratory
sarcoidosis were reported to the Danish Institute of Clinical Epidemiology. Among
them 48 patients developed a malignant tumour, the follow-up period ending on
31 December 1971. Only 33-8 cases of cancer were expected if sarcoidosis patients
had had the same rates as the general population; the difference between the expected
and observed number is statistically significant (0.02 > P > 0.01). Malignant
lymphomata occurred 11 times and lung cancer 3 times more frequently than
expected. For all other forms of cancer taken together, there was no significant
difference between the expected and the observed number of cases.
The increased cancer incidence may result from immunological deficiencies in
patients with sarcoidosis.
ACCORDING to the theories of immuno-
logical surveillance in the human body, an
intact immune apparatus is one of the
conditions necessary to prevent or limit
the development of malignant tumours.
Thus a certain number of congenital,
idiopathic or iatrogenic disturbances of
the immune apparatus are known to be
associated with an increased incidence of
cancer, particularly of malignant lympho-
mata (Keast, 1970; Doll and Kinlen,
1970).
Since various immunological distur-
bances usually accompany sarcoidosis
(Chase, 1966), it might be reasoned that
this disease could be associated with an
increased incidence of malignant tumours,
but studies ofthe incidence ofmalignancies
in large series of sarcoidosis patients have
apparently not been published. Case
histories which show an association be-
tween sarcoidosis and malignant lympho-
mata or lung cancerhave been reviewed by
Brincker (1972) and Sakula (1963). These
studies did not allow estimation of the
frequency of the association of sarcoidosis
with a malignancy. However, in Brinc-
ker's study (1972) 5 cases of true sarcoi-
dosis were found in about 1500 cases of
malignant lymphoma. This rate is very
high in view of the fact that sarcoidosis
occurs with an incidence of 5 per 100,000
in the general population (Horwitz, 1967;
Horwitz, Payne and Wilbek, 1967). It
seems remarkable that sarcoidosis has
been diagnosed before malignant disease
in all recorded instances ofthis association.
The above observations suggest the
possibility of an increased incidence of
malignancies in patients with sarcoidosis.
The present study was undertaken in
order to test this hypothesis.
MATERIALS AND METHODS
Background.-Since 1962 all new cases of
respiratory sarcoidosis diagnosed in Danish
chest clinics have been reported to a central
registry in The Danish Institute of Clinical
Epidemiology (DICE) (previously the Danish
Tuberculosis Index). This material repre-
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sents most cases of sarcoidosis diagnosed in
Denmark, but a certain reporting deficit
exists as some patients are diagnosed and
treated in hospital departments other than
the chest clinics and hence are not reported to
the central register. The true size of this
deficit is unknown but spot checks indicate a
figure between 17 and 31 per cent (Alsbirk,
1964; R0mer et al., 1973). The unreported
cases probably represent more severe sympto-
matic forms of the disease.
Clinical and epidemiological data of the
sarcoidosis patients reported to DICE have
been described in detail elsewhere (Horwitz
et al., 1967). The sex ratio was 1: 1, the
median age 32 years. Half of the patients
had only involvement of the hilar lymph
nodes; the other half had a pulmonary lesion
with or without hilar involvement.
Since 1943 all new cases of malignant
tumours diagnosed in Denmark should have
been reported to the Danish Cancer Registry.
The percentage of deaths being recorded
from death certificates only had dropped to
8 in 1959, but there is no reporting deficit for
cancer deaths since all death certificates are
matched against the files of the Cancer
Registry. There is no reason to believe that
the reporting deficit is greater than 8 per cent
innon-fatal disease. Since the latter patients
represent only 25-30 per cent of the total
cases, the combined reporting deficit for all
cancer cases presumably does not exceed 2-
2-4 per cent. The activities of the Danish
Cancer Registry have been described in detail
elsewhere (Clemmesen, 1965).
During the decade 1962-71, 2561 newly
diagnosed cases ofrespiratory sarcoidosis were
reported to the central register. In Sep-
tember 1972 all the notifications were match-
ed against the files of the Cancer Registry in
order to see which sarcoidosis patients had a
record in the Cancer Registry. All cases of
cancer which had occurred before 1 January
1972 were registered and from the search
through the records it was found that 65
patients had been registered with a malignant
disease.
In 17 patients the tumour was demon-
strated before the diagnosis ofsarcoidosis and
they were therefore excluded. In the re-
maining 48 patients the malignancy was
diagnosed simultaneously with, or after,
sarcoidosis and the present study consists of
those patients. The basic population thus
consists of2544 patients (1292 males and 1252
females) with sarcoidosis, who had not had
cancer previously.
Table I shows the distribution of the 48
cancer cases by diagnosis; none ofthe patients
TABLE I. Cases of Malignant Tumours
Diag,nosed Simultaneously with or after
Sarcoidosis
Localization of
primary Males Females Total
Stomach
Colon
Liver
Pancreas
Lung
Breast
Cervix uteri
Corpus uteri
Ovary
Vulva
Prostate
Penis
Kidney
Ureter
Urinary bla(dder
Skin
Thymus
Lymphosarcoma
Hodgkin's disease
Total
1
2
1
8
1
1
1
1
4
1
3
I
2 3
2
1 2
1 9
3 4
3 3
1 1
3 3
1 1
1
1 1 1
3 7
1 1
1 2
1 4
26 22 48
had more than one malignant disease. The
number of men and women was fairly equal
(26 and 22 respectively). Apart from cancer
of the female reproductive system, lung
cancer represents a marked sex difference as
8 of the 9 cases occurred in men. The
remainder were 13 cases of urogenital cancer,
8 cases of cancer ofthe digestive tract, 7 cases
of skin cancer, 7 cases of malignancies of
lymph nodes and thymus and 4 cases of
breast cancer.
In order to calculate the expected number
of cancer cases, the sarcoidosis patients were
broken down by year of report, i.e., those
reported in 1962, 1963 etc.; within each of
these groups, the patients were split by sex
and age. The sex and age specific incidence
of cancer in the Danish general population
(average for 1963-67) was applied to each of
these cells. Although the entire observation
period 1962-71 is not covered by the 1963-67
cancer incidence rates, the latter were used
for the calculations because theyrepresent the
latest available Danish figures (Clemmesen.
1973, personal communication). The expect-
ed number depends, of course, on the length
ofthe period at risk. The onset ofthis period
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was reckoned from the year that the sarcoi-
dosis was reported in the register, and runs up
to 1 January 1972; the period was thus on an
average 91 years for those reported in 1962,
81 years for those reported in 1963 and so on,
until for those reported in 1971 it was half a
year. When the calculations were made,
regard was also paid to the factor that the
patient's age increased during the period of
observation. The expected number of all
forms of cancer taken together was calculated
but special estimates were made for lung
cancer and malignant lymphoma, based on
the respective rates for the two diseases.
The following formula has been used to
calculate the significance levels:
=x/n p 1/2n
V/p(l p)/n
where
x = number of cancer cases observed
p = expected cancer morbidity
n = number of observation years. n = 12,240
person-years in the calculations covering all
10 years of observation, and 8065 person-years
in the calculations covering only the first
4 years of observation.
No review was made ofthe case records in
order to check the diagnosis of any of the 48
patients who had both sarcoidosis and
cancer; a rejection of the diagnosis in one or
more of these cases would merely result in a
statistically unacceptable alteration in the
basis for the calculations.
RESULTS
Table II shows that 48 cases of cancer
were observed, whereas only 33.8 cases
were expected. This difference is statisti-
cally significant (0-02 >P > 0 01). The
higher incidence is due primarily to an
increased number of cases in males,
particularly oflung cancer. Nine cases of
lung cancer were found but only 2-8 cases
were expected; this difference is highly
significant (P < 0 001). Six cases of
malignant lymphoma occurred whereas
only 0 5 cases were expected; this dif-
ference is also highly significant
(P < 0 001). With regard to all other
forms of cancer, there is no significant
difference between the expected and the
observed number of cases (30.5 cases vs
33).
Table III shows that the expected
number of cancer cases goes down with
lapse of time. This results from the fact
that only the patients reported in 1962
had up to 10 years follow-up; those
reported in 1962 + 1963 had 9 years
follow-up; those reported in 1962 + 1963
+ 1964 had 8 years follow-up etc. In
other words, the number ofpatients at risk
is high for short intervals and decreases
the longer the interval becomes. The
expected incidence goes up gradually
because the patients' age increases during
the observation period; hence the risk of
cancer also increases. It is striking that
the observed cancer incidence is very high
during the first 4 follow-up years; there-
after it drops to the normal level or per-
TABLE II. Expected and Observed Cancer Incidence in 2544 Patients with Respiratory
Sarcoidosis
All types of cancers
Males
Females
Total
Symptomatic cases
No symptoms
Cancer of lung
M.ales
Females
Total
Malignant lymphomata
Males
F'emales
Total
No. of cases with
malignant tumours
Expected Observed
136-6
20-2
33-8
2:3-2
10-6
2-2
0-6
2-8
0-:32
0-20
0-52
26
22
48
35
13
8
I
9
4
2
6
Inciclence per I1000
person-years
Expected Observed
2* 20
3. 33
2 - 76
3-79
1 *73
0-36
0* 10
0-23
0 05
0 03
0 04
4-21
:3-62
:3 92
5-71
2 - 13
1 30
0* 16
0 74
0 *65
0 33
0 49
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TABLE III.-Expected and Observed Cancer Incidence (All Forms) by Year in Follow-up
Period
No. of cases with
malignant tumours
Year in follow-up , A
period Expected Observed
1st
2nd
3rd
4th
5th
6th
7th
8th
9th
10th
6-0
5-6
5 - 1
4-5
3-7
3-0
2-6
2-1
1-2
0-3
13
6
7
12
2
4
4
haps a little lower. In other words, an
excess morbidity exists only in the first
4 years after sarcoidosis was diagnosed.
During this period, 38 cases of cancer were
observed whereas only 21-2 cases were
expected; the difference is highly signifi-
cant (P < 0-001).
DISCUSSION
The diagnosis ofrespiratory sarcoidosis
is beset with some uncertainty. A posi-
tive Kveim reaction is confirmative butthe
test is used only to a limited extent in
Denmark. A number of other diseases
which present similar roentgenological
findings may therefore be confused with
sarcoidosis and be reported. As a con-
sequence one might expect that some cases
oflung cancer and malignant lymphomata
would be reported to DICE under a
diagnosis of sarcoidosis. When the true
nature ofthe disease became evident, then
the case would be reported to the Cancer
Registry. Conversely, true cases of sar-
coidosis may be reported to the Cancer
Registry as, say, lung cancer or malignant
lymphomata. However, this possibility is
considerably less likely to occur because
most cases of cancer are verified histo-
logically, whereas only about half of the
sarcoidosis cases are verified by this
means.
Thus, the problem is whether the 9
cases of lung cancer and the 6 cases of
malignant lymphomata represent genuine
Incidence per 1000 person-years
Expected Observed
2-49 254405-40
2 60 2-54 2-78 4-16
2-68 2-73 3-68 5-42
2-78 7-49
54 2-86 2-90 1-54 2-57
3-20 3-28 657 2-83 3:39 6 . 25 8
3 56 3-56 3.57
associations of sarcoidosis and cancer, or
whether these cases or some of them
represent a mistaken diagnosis of one or
both diseases. The likelihood ofagenuine
association is greater the longer the inter-
val between the time of diagnosis of
sarcoidosis and the time of diagnosis of
cancer. In 4 ofthe 9 cases oflung cancer
more than one year passed; in 4 of the 6
cases ofmalignant lymphomata more than
2 years passed between the two diagnoses.
These 8 cases probably represent true
associations. In 4 ofthe 5 patients where
lung cancer was diagnosed during the first
year after the diagnosis of sarcoidosis,
biopsies are available showing both non-
caseating epithelioid cell granulomata and
tumour tissue. Similarly, in one of the
2 patients in whom malignant lymphoma
was diagnosed within the first year after
sarcoidosis, a biopsy also containing non-
caseating epithelioid cell granulomata
exists.
On the basis of these data (the time
intervals and the biopsy findings), at least
8 ofthe 9 cases oflung cancer and 5 ofthe
6 cases of malignant lymphomata appear
to represent genuine associations of sar-
coidosis and cancer. Still, it must be
borne in mind that sarcoid reactions may
be seen in lymph nodes from patients with
lung cancer (Sakula, 1963) or malignant
lymphomata (Brincker, 1972); this reac-
tion should not be considered as sarcoidosis
disease.
Ifwe assume thatpatients withrespira-
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tory sarcoidosis really have an increased
frequency of lung cancer and malignant
lymphomata, it is natural to ask why this
is so. As regards lung cancer, the chronic
pulmonary changes caused by sarcoidosis
may act as an additional carcinogenic
stimulus; it may also be that these changes
lead to a decreased resistance to other
carcinogenic stimuli. The increased inci-
dence of malignant lymphomata may
result from the immunological defects
often noted in sarcoidosis patients; thisisin
line with the increased incidence of
malignant lymphomata in patients who
have immunological defects (Keast, 1970;
Doll and Kinlen, 1970). Some of the
sarcoidosis patients were treated with
corticosteroids but since details of the
treatment are not known in the central
register, it cannot be determined what
influence the steroid therapy may have
had on the cancer incidence.
Since the present study is based on
information from matching between two
central registries, the question may be
posed whether or not the incidence of
malignant tumours in the sarcoidosis
patients is too low because of a reporting
deficit. As mentioned previously, the
reporting deficit concerning the malignant
disease is negligible and plays no role. As
regards sarcoidosis, the moderate reporting
deficit might at first sight seem of no
importance since the basis of the study is
those cases which were in fact reported.
However, the most severe cases of sarcoi-
dosis are probably not reported to DICE as
they are treated only in the medical de-
partments. The present series is therefore
likely to be dominated by the findings in
mild, non-symptomatic cases. Such
patients may have higher immunity and
therefore also a lower cancer risk, if the
incidence of malignant tumours is pro-
portional to the degree of the immuno-
logical defect, and hence also the severity
of the sarcoidosis. As the mild cases con-
stitute about half of the present series,
this might explain why the increased
incidence of cancer was confined to lung
cancer and malignant lymphomata. This
hypothesis is supported by the fact that
patients with symptomatic sarcoidosis had
an observed cancer incidence which was
1-5 times higher than expected; among the
non-symptomatic cases the ratio was only
1*2 times higher (see Table II). Thus, this
fact also supports the assumption and
previously quoted data indicating that a
genuine association exists between cancer
and sarcoidosis.
We are indebted to Johannes Clem-
mesen and his staff at the Danish Cancer
Registry for tracing the 2561 patients with
sarcoidosis in the files of the Cancer
Registry. Johannes Clemmesen also
kindly placed at our disposal unpublished
Danish cancer incidence figures for the
years 1963-67.
This study has been supported by a
grant fromthe DanishAnti-CancerLeague.
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